Price Alert

CASI Pharmaceuticals Inc. (CASI)

NASDAQ: CASI · Real-Time Price · USD

2.35

0.41 (21.13%)

At close: Aug 15, 2025, 3:59 PM

2.00

-14.89%

After-hours: Aug 15, 2025, 07:47 PM EDT

21.13% (1D)

Bid	1.99
Market Cap	36.41M
Revenue (ttm)	31.37M
Net Income (ttm)	-40.48M
EPS (ttm)	-2.54
PE Ratio (ttm)	-0.93
Forward PE	-1.01
Analyst	Buy

Ask	2.01
Volume	5,935,092
Avg. Volume (20D)	1,213,196
Open	1.96
Previous Close	1.94
Day's Range	1.91 - 3.05
52-Week Range	1.09 - 7.67
Beta	0.61

About CASI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CASI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

CASI Pharmaceuticals Inc. is scheduled to release its earnings on Aug 26, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+51.16%

CASI Pharmaceuticals shares are trading higher aft... Unlock content with Pro Subscription

4 months ago

+0.95%

CASI Pharmaceuticals shares are trading higher after the company received a $20 million proposal from CEO Dr. Wei-Wu He to acquire its business operations in China.

News

1 week ago · accessnewswire.com

CASI Pharmaceuticals Announces FDA Clearance of IND Application for CID-103 in Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitope Phase 1 study in adults with active and chronic active renal allograft AMR planned to initiate AMR is ...

3 weeks ago · accessnewswire.com

CASI Pharmaceuticals Appoints David Cory as Chief Executive Officer to Lead U.S. Company Focused on Clinical Development of CID-103, a Potential Best in Class Anti-CD38 Program

-- David Cory is an industry veteran, bringing more than 30 years of operational experience, in private and public, emerging-stage biotech and large pharma companies with an established track record o...

2 months ago · accessnewswire.com

CASI Pharmaceuticals Provides Business and Clinical Update

BEIJING, CHINA / ACCESS Newswire / May 19, 2025 / CASI Pharmaceuticals, Inc. (Nasdaq:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commerc...

3 months ago · accessnewswire.com

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

BEIJING, CN / ACCESS Newswire / May 16, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), ("CASI" or the "Company"), a Cayman incorporated biopharmaceutical company focused on developing and commercial...